Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04320069 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study
A NA study, sponsored by Insulet Corporation.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT04320069: Completed NA study, sponsored by Insulet Corporation.
NCT04320069 is a NA study that has completed, run by Insulet Corporation. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04320069, a NA study, has completed, sponsored by Insulet Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
Subjects will use the Omnipod Horizon™ System in Manual Mode in an outpatient setting for 14-days. Subjects will be trained to use the Manual Mode feature of the Omnipod Horizon™ System including how to use the bolus calculator using manual entry of blood glucose values or by using the CGM-informed bolus calculator.
Primary Outcome
Glucose metric from continuous glucose monitoring system (CGM)
Interventions
- DEVICE Omnipod Horizon™ Automated Glucose Control System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-06-09 |
| Est. Completion | 2020-09-29 |
| Phase | NA |
What the finished NCT04320069 record still lists
NCT04320069 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Omnipod Horizon™ Automated Glucose Control System is the first listed.
NCT04320069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04320069 about?
NCT04320069 is a clinical study titled "Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study". Subjects will use the Omnipod Horizon™ System in Manual Mode in an outpatient setting for 14-days. Subjects will be trained to use the Manual Mode feature of the Omnipod Horizon™ System including how to use the bolus calculator using manual entry of blood glucose values or by using the CGM-informed ...
What is the current status of trial NCT04320069?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2020-06-09. Estimated completion is 2020-09-29.
What interventions are being tested in trial NCT04320069?
The interventions under investigation include: Omnipod Horizon™ Automated Glucose Control System (DEVICE).
Who is sponsoring clinical trial NCT04320069?
This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04320069's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI